Investigational drugs for endometriosis

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 399-407

  Chlouber, Richard O ^a   Olive, David L ^a   Pritts, Elizabeth A ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Angiogenesis; Aromatase; Endometriosis; Estrogen receptor agonist; Gonadotropin releasing hormone antagonists; Immune; Matrix metalloprotease; Pelvic pain; Selective progesterone receptor modulator

Indexed keywords

ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTIGESTAGEN; AROMATASE INHIBITOR; ASOPRISNIL; CETRORELIX; ESTRADIOL; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOMODULATING AGENT; J 1042; J 912; J 956; LETROZOLE; MATRIX METALLOPROTEINASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MESOPROGESTIN DERIVATIVE; MIFEPRISTONE; NEW DRUG; NORETHISTERONE ACETATE; ONAPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 135695; ZK 137316;

BLEEDING DISORDER; BLOATING; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIOSIS; ENDOMETRIUM HYPERPLASIA; FEMALE FERTILITY; FLUID RETENTION; HOT FLUSH; HUMAN; HYPERCORTISOLISM; LIBIDO DISORDER; LIVER DYSFUNCTION; MOOD DISORDER; NONHUMAN; OVARY INSUFFICIENCY; PAIN; PATHOPHYSIOLOGY; PELVIS PAIN SYNDROME; REPRODUCTION; REVIEW; SIDE EFFECT; SUBFERTILITY; SYMPTOMATOLOGY; VAGINA DISEASE;

AROMATASE INHIBITORS; DRUGS, INVESTIGATIONAL; ENDOMETRIOSIS; FEMALE; HORMONE ANTAGONISTS; HUMANS;

EID: 33645723454     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.399     Document Type: Review

References (61)

1. OLIVE DL: Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat. Endocrinol. (2004) 3(2):83-89.
2. FRIEDMAN AJ, LOBEL SM, REIN MS, BARBIERI RL: Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. (1990) 78:943.
3. JONES RC: The effect of a luteinizing hormone-releasing hormone antagonist on experimental endometriosis in the rat. Acta Endocrinol. (1987) 114:370-382.
4. MARTHA PM, GRAY ME, CAMPION M et al: Initial safety profile and hormonal dose response characteristics of the pure GnRH antagonist, Abarelix-depot, in women with endometriosis. VIII World Congress on Endometriosis, San Diego, USA (24 - 27 February 2005) (Poster).
5. KUPKER W, FELDBERBAUM RE, KRAPP M, SCHILL T, MALIK E, DIEDRICH K: Use of GnRH antagonists in the treatment of endometriosis. Reprod. Biomed. Online (2002) 5(1):12-16.
6. BULUN SE, ZEITOUN KM, TAKAYAMA K et al.: Molecular basis for treating endometriosis with aromatase inhibitors. Hum. Reprod. Update (2000) 6:413-418.
7. EBERT AD, BARTLEY J, DAVID M: Aromatase inhibitors and cylooxygenase-2 (COX-2) inhibitors in endometriosis: new questions-old answers? Eur. J. Obstet. Gynecol. Reprod. Biol. (2005) 122:144-150.
8. MERSEMAN GF, BILOTAS M, ABELLO V et al: Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil. Steril. (2005) 84(2):459-463.
9. YANO S, IKEGAMI Y, NAKAO K: Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimitelforschung (1996) 46(2):192-195.
10. KUDOH M, SUSAKI Y, IDEYAMA Y, NANYA T, MORI M, SHIKAMA H: Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J. Steroid Biochem. Mol. Bio. (1997) 63(1-3):75-80.
11. RAZZI S, FAVA A, SARTINI A, DE SIMONE S, COBELLIS L, PETRAGLIA F: Treatment of severe endometriosis with an aromatase inhibitor in a young ovariectomized woman. BJOG (2004) 111:182-184.
12. TAKAYAMA K, ZEITOUN K, GUNBY RT, SASANO H, CARR BR, BULUN SE: Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil, Steril. (1998) 69(4):709-713.
13. FATEMI HM, AL-TURKI HA, PAPANIKOLAOU E, KOSMAS L, DE SUTTER P, DEVROEY P: Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod. Biomed. Online (2005) 11(4):455-457.
14. SHIPPEN ER, WEST WJ Jr: Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil. Steril. (2004) 81(5):1395-1398.
15. SOYSAL S, SOYSAL ME, OZER S, GUL N, GEZGIN T: The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum. Reprod. (2004) 19(1):160-167.
16. AILAWADI RK, JOBANPUTRA S, KATARIA M, GURATES B, BULUN SE: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil. Steril. (2004) 81(2)-290-296.
17. AMSTERDAM LL, GENTRY W, JOBANPUTRA S, WOLF M, RUBIN SD, BULUN SE: Anastrozole and oral contraceptives: a novel treatment for endometriosis. Fertil. Steril. (2005) 4(2):300-304.
18. CHWALISZ K, BRENNER RM, FUHRMANN UU et al.: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids (2000) 65(10-11):741-751.
19. PHILIBERT D: RU38486: an original multifaceted antihormone in vivo. In: Adrenal steroid antagonism, Agarwal M (Ed.), Walter de Gruy and Co., Berlin, Germany (1984):77-101.
20. LEONHARDT SA, BOONYARATANAKORNKIT V, EDWARDS DP: Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids (2003) 68(10-13):761-770.
21. SPITZ IM, CHWALISZ K: Progesterone receptor modulators and progesterone antagonists in women's health. Steroids (2000) 65(10-11):807-815.
22. TJADEN B, GALETTO D, WOODRUFF JD, ROCK JA: Time-related effects of Mifepristone treatment in experimentally induced endometriosis in the rat. Fertil. Steril. (1993) 59(2):437-440.
23. GROW DR, WILLIAMS RF, HSIU JG, HODGEN GD: Antiprogestin and/or Gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J. Clin. Endocrinol. Metab. (1996) 81(5):1993-1999.
24. KETTEL LM, MURPHY AA, MORALES AJ, YEN SS: Clinical efficacy of the antiprogesterone mifepristone in the treatment of endometriosis and uterine fibroids. Hum. Reprod. (1994) 9(Suppl. 1):116-120.
25. KETTEL LM, MURPHY AA, MORALES AJ, ULMANNA, BAULIEU EE, YEN SS: Treatment of endometriosis with the antiprogesterone RU486 (mifepristone). Fertil. Steril. (1996) 65(1):23-28.
26. KETTEL LM, MURPHY AA, MORALES AJ, YEN SS: Preliminary reports on the treatment of endometriosis with low-dose RU486 (mifepristone). Am. J. Obstet. Gynecol, (1998) 178(6):1151-1156.
27. JIANG J, LU J, WU R: Mifepristone following conservative surgery in the treatment of endometriosis. Zhonghua Fu Chan Ke Za Zhi (2001) 36(12):717-720.
28. STEINAUER J, PRITTS EA, JACKSON R, JACOBY AF: Systematic review of Mifepristone for the treatment of uterine leioyomata. Obstet. Gynecol. (2004) 103(6)1331-1336.
29. FOLKMAN J, SHING Y: Angiogenesis. J. Biol. Chem. (1992) 267:10931-10934.
30. OLIVE DL: Medical therapy of endometriosis. In: Endometriosis in clinical practice, Olive DL (Ed.), Taylor and Francis, New York, USA (2005):173-193.
31. NAP AW, DUNSELMAN GA, GRIFFIOEN AW, MAYO KH, EVERS JL, GROOTHUIS PG: Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil. Steril. (2005) 83(3):793-795.
32. HULL ML, CHARNOCK-JONES DS, CHAN CLK et al.: Antiangiogenic agents are effective inhibitors of endometriosis. J. Clin. Endocrinol. Metab. (2003) 88:2889-2899.
33. NAP AW, GRIFFIOEN AW, DUNSELMAN GAJ et al: Antiangiogenesis therapy for endometriosis. J. Clin. Endocrinol. Metab. (2004) 89(3):1089-1095.
34. BECKER CM, SAMPSON DA, RUPNICK MA et al: Endostatin inhibits the growth of endometriosis lesions but does not affect fertility. Fertil. Steril. (2005) 84(Suppl. 2):1144-1155.
35. SCARPELLINI F, SBRACIA M, LECCHINI S, SCARPELLINI L: Anti-angiogenesis treatment with thalidomide in endometriosis: as pilot study. Fertil. Steril. (2002) 78:S87.
36. OSTEEN KG, YEAMAN GR, BRUNER-TAN K: Matrix metalloproteinases and endometriosis. Sem. Reprod. Med. (2003) 21:155-163.
37. SALAMONSEN LA, WOOLLEY DE: Matrix metalloproteinases in normal menstruation. Hum. Reprod. (1996) 11:124-133.
38. GILABERT-ESTELLES J, ESTELLS A, GILABERT J et al: Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum. Reprod. (2003) 18(7):1516-1522.
39. UEDA M, YAMASHITA Y, TAKEHARA M et al.: Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol. Endocrinol. (2002) 16:391-402.
40. UZAN C, CORTEZ A, FAUVET R, SIFFROI JP, DARAI E: Eutopic endometrium and peritoneal, ovarian and bowel endometriotic tissue express a different profile of matrix metalloproteinases-2, -3, and -11, and of tissue inhibitor metalloproteinases-1 and -2. Birchows Arch. (2004) 445(6):603-609.
41. LAUDANSKI P, SZAMATOWICZ J, RAMEL P: Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis. Gynecol. Endocrinol. (2005) 21(2):106-110.
42. LECCE G, MEDURI G, ANCELIN M, BERFERON C, PERROT-APPLANAT M: Presence of estrogen receptor β in the human endometrium throughout the cycle: expression in glandular, stromal, and vascular cells. J. Clin. Endocrinol. Metab. (2001) 86:1379-1386.
43. FUJIMOTO J, HIROSE R, SAKAGUCHI H, TAMAYA T: Expression of estrogen receptor α and β in ovarian endometriomata. Mol. Hum. Reprod. (1999) 5:742-747.
44. HUDELIST G, KECKSTEIN J, CZERWENKA K et al: Estrogen receptor β and matrix metalloproteinase-1 are coexpressed in uterine endometrium and endometriotic lesions of patients with endometriosiS. Fertil. Steril. (2005) 84(Suppl. 2):1249-1256.
45. HARRIS HA, BRUNER-TRAN KL, ZRANG X, OSTEEN KG, LYTTLE CR: A selective estrogen receptor-β agonist causes lesion regression in an experimentally induced model of endometriosis. Hum. Reprod. (2005) 20(4):936-941.
46. KAYISLI UA, MAHUTTE NG, ARICI A: Uterine chemokines in reproductive physiology and pathology. Am. J. Reprod. Immunol. (2002) 47(4):213-221.
47. D'HOOGHE TM, KYAMA C, DEBROCK S, MEULEMAN C, MWENDA JM: Future directions in endometriosis research. Ann. NY Acad. Sci. (2004) 1034:316-325.
48. SIDELL N, HAN SW, PARTHASARATHY S: Regulation and modulation of abnormal immune responses in endometriosis. Ann. NY Acad. Sci. (2002) 955:159-173.
49. SOMIGLIANA E, VIGANO P, ROSSI G, CARINELLI S, VIGNALI M, PANINA-BORDIGNON P: Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum. Reprod. (1999) 17:555-559.
50. KEENAN JA, WILLIAMS-BOYCE PK, MASSEY PJ, CHEN TT, CLAUDLE MR, BUKOVSKY A: Regression of endometrial explants in a rat model of endometriosis treated with the immune modulators loxoribine and levamisole. Fertil. Seril. (1999) 72:135-141.
51. LEBOVIC DI, KIR M, CASEY CL: Peroxisome proliferators-activated receptor-γ induces regression of endometrial explants in a rat model of endometriosis. Fertil. Steril. (2004) 82(Suppl. 3):1008-1013.
52. 2b on endometrioma cells in vitro. Obstet. Gyneocl. (2001) 98(3):417-420.
53. 2b in a murine model. Fertil. Steril. (1999) 71:907-911.
54. 2β therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil. Steril. (2002) 78(4):705-711.
55. STEINLEITNER A, LAMBERT H, ROY S: Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated infertility. Fertil. Steril. (1991) 55:26-31.
56. BALASCHI J, CREUS M, FABREGUES F et al: Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum. Reprod. (1997) 12:2046-2050.
57. ROJAS-CARTAGENA C, APPLEYARD CB, SANTIAGO OI, FLORES I: Experimental intestinal endometriosis is characterized by increased levels of soluble TNFRSF1B and downregulation of TNFRSF1A and TNFRSF1B gene expression. Biol. Reprod. (2005) 73(6):1211-1218.
58. GAO Y, LUO L, HE F: Effect of IL-I-β and TNF-α on the expression of monocyte chemotactic protein-1 in endometriotic cells. J. Tongji Med. Univ. (1999) 19(3):212-214.
59. D'ANTONIO M, MARTELLI F, PEANO S, PAPOIAN R, BORRELLI F: Abilit of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J. Reprod. Immunol. (2000) 48:81-98.
60. BARRIER BE, BATES GW, LELAND MM, LEACH DA, ROBINSON RD, PROPST AM: Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis baboons. Fertil. Steril. (2004) 81(Suppl. 1):775-779.
61. D'HOOGHE TM, NUGENT NP, CUNEO S et al.: Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons; a prospective, randomized, placebo and drug controlled study. Biol. Reprod. (2005):21.